Arcus Biosciences - Stock Price History | RCUS
Historical daily share price chart and data for Arcus Biosciences since 2023 adjusted for splits. The latest closing stock price for Arcus Biosciences as of March 31, 2023 is 18.24.
- The all-time high Arcus Biosciences stock closing price was 48.47 on November 23, 2021.
- The Arcus Biosciences 52-week high stock price is 39.75, which is 117.9% above the current share price.
- The Arcus Biosciences 52-week low stock price is 15.70, which is 13.9% below the current share price.
- The average Arcus Biosciences stock price for the last 52 weeks is 24.39.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Arcus Biosciences Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2022 |
27.9756 |
41.8300 |
41.8300 |
17.2300 |
20.6800 |
-48.90% |
| 2021 |
33.3197 |
26.1600 |
48.4700 |
22.7500 |
40.4700 |
55.89% |
| 2020 |
21.5422 |
9.8600 |
36.5600 |
8.7800 |
25.9600 |
157.03% |
| 2019 |
9.3063 |
10.6800 |
13.3800 |
6.4400 |
10.1000 |
-6.22% |
| 2018 |
13.5637 |
17.0000 |
17.7100 |
9.7400 |
10.7700 |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.318B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
